These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
524 related articles for article (PubMed ID: 17304444)
1. Prolonged QT interval and torsades de pointes associated with atazanavir therapy. Ly T; Ruiz ME Clin Infect Dis; 2007 Mar; 44(6):e67-8. PubMed ID: 17304444 [TBL] [Abstract][Full Text] [Related]
2. Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes. Prescrire Int; 2009 Jun; 18(101):104. PubMed ID: 19637415 [TBL] [Abstract][Full Text] [Related]
3. Takotsubo cardiomyopathy and QT interval prolongation: who are the patients at risk for torsades de pointes? Samuelov-Kinori L; Kinori M; Kogan Y; Swartzon M; Shalev H; Guy D; Ferenidou F; Mashav N; Sadeh B; Atzmony L; Kliuk-Ben-Basat O; Steinvil A; Justo D J Electrocardiol; 2009; 42(4):353-357.e1. PubMed ID: 19261294 [TBL] [Abstract][Full Text] [Related]
9. Torsades de pointes related to transient marked QT prolongation following successful emergent percutaneous coronary intervention for acute coronary syndrome. Kawabata M; Hirao K; Takeshi S; Sakurai K; Inagaki H; Hachiya H; Isobe M J Electrocardiol; 2008; 41(2):117-22. PubMed ID: 18328336 [TBL] [Abstract][Full Text] [Related]
10. Urolithiasis in HIV-positive patients treated with atazanavir. Couzigou C; Daudon M; Meynard JL; Borsa-Lebas F; Higueret D; Escaut L; Zucman D; Liotier JY; Quencez JL; Asselah K; May T; Neau D; Vittecoq D Clin Infect Dis; 2007 Oct; 45(8):e105-8. PubMed ID: 17879904 [TBL] [Abstract][Full Text] [Related]
11. HIV protease inhibitors induced prolongation of the QT Interval: electrophysiology and clinical implications. Singh M; Arora R; Jawad E Am J Ther; 2010; 17(6):e193-201. PubMed ID: 19636247 [TBL] [Abstract][Full Text] [Related]
12. Takotsubo cardiomyopathy as a potential cause of long QT syndrome and torsades de pointes. Ghosh S; Apte P; Maroz N; Broor A; Zeineh N; Khan IA Int J Cardiol; 2009 Aug; 136(2):225-7. PubMed ID: 18617280 [TBL] [Abstract][Full Text] [Related]
13. Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy. Keivanidou A; Arnaoutoglou C; Krommydas A; Papanikolaou G; Tsiptses K; Chrisopoulos C; Kirpizidis C Cardiol J; 2009; 16(2):172-4. PubMed ID: 19387967 [TBL] [Abstract][Full Text] [Related]
14. The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias. Topilski I; Rogowski O; Rosso R; Justo D; Copperman Y; Glikson M; Belhassen B; Hochenberg M; Viskin S J Am Coll Cardiol; 2007 Jan; 49(3):320-8. PubMed ID: 17239713 [TBL] [Abstract][Full Text] [Related]
15. [Takotsubo cardiomyopathy associated with torsades de pointes and long QT interval: a case report]. Okada T; Miyata S; Hashimoto K; Maie K; Mochizuki S J Cardiol; 2007 Jul; 50(1):83-8. PubMed ID: 17685032 [TBL] [Abstract][Full Text] [Related]
16. QT interval prolongation, torsade de pointes and renal disease. Patanè S; Marte F; Di Bella G; Currò A; Coglitore S Int J Cardiol; 2008 Nov; 130(2):e71-3. PubMed ID: 18255176 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977 [TBL] [Abstract][Full Text] [Related]
18. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines. Arbel Y; Swartzon M; Justo D Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403 [TBL] [Abstract][Full Text] [Related]
19. QT interval prolongation and torsades de pointes due to erythromycin lactobionate. Oberg KC; Bauman JL Pharmacotherapy; 1995; 15(6):687-92. PubMed ID: 8602374 [TBL] [Abstract][Full Text] [Related]
20. [Amiodarone therapy after sotalol-induced torsade de pointes: prolonged QT interval and QT dispersion in differentiation of pro-arrhythmic effects]. van de Loo A; Klingenheben T; Hohnloser SH Z Kardiol; 1994 Dec; 83(12):887-90. PubMed ID: 7846927 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]